FDA Investigating: US Patient Dies After Use of Placental Extract Laennec, Russian Med Student Also Died

Key Takeaways

• FDA reports US death linked to self‑administered Laennec.
• Russian influencer died; friend suffered severe illness.
• Product imported illegally, lacks FDA approval.
• IV use and counterfeit versions increase infection risk.
• Wellness fads drive unsafe self‑injection of biologics.

Summary

The U.S. Food and Drug Administration has opened an investigation after a patient died following self‑injection of Laennec, an allogeneic placental extract imported from Japan. A similar fatality occurred in Russia involving health influencer Anna Kolyada, whose companion fell seriously ill. Laennec, approved in Japan for liver support, is being used off‑label and often administered intravenously despite lacking U.S. approval. The deaths highlight illegal importation, counterfeit products, and the growing trend of unsupervised biologic use promoted by wellness influencers.

Pulse Analysis

Laennec, a placental extract produced by Japan Bio Products, has been marketed in Japan since the 1970s for liver function support. In the United States, the product is unapproved, yet it circulates through informal channels and is often repurposed for off‑label claims ranging from anti‑aging to immune boosting. The lack of regulatory oversight enables cross‑border shipments that violate the Federal Food, Drug, and Cosmetic Act, creating a gray market where counterfeit or improperly stored batches can reach consumers without quality guarantees.

The recent fatalities underscore the medical dangers of self‑administration. Intravenous delivery of a product designed for subcutaneous injection can trigger severe immune reactions, while inadequate mixing or storage—evident in the Russian case—facilitates bacterial contamination and sepsis. Both incidents involved individuals acting on social‑media advice rather than licensed medical guidance, illustrating how misinformation amplifies risk. These events also raise concerns about broader biologic misuse, including peptide and stem‑cell trends that have already resulted in injuries and deaths.

Beyond the immediate health impact, the Laennec cases signal a widening regulatory challenge for the FDA and international partners. As wellness influencers continue to promote unproven biologics, authorities may intensify import inspections, issue warning letters, and pursue legal action against illicit distributors. Consumers and clinicians alike must remain vigilant, demanding evidence‑based therapies and reporting adverse events promptly to curb a burgeoning public‑health threat.